Search

Displaying results 851 - 860 of 8515 in total
  1. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    erythematosus, but so far only anifrolumab has been approved. … [A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]

  2. Drug

    Biperiden

    go.drugbank.com/drugs/DB00810
    ApprovedInvestigationalWithdrawn

    A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. … It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.

  3. Drug

    Spironolactone

    go.drugbank.com/drugs/DB00421
    ApprovedInvestigational

    [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243] … [A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.

  4. Drug

    Calaspargase pegol

    go.drugbank.com/drugs/DB14730
    ApprovedInvestigational

    Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890]. … Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].

  5. Drug

    Semaglutide

    go.drugbank.com/drugs/DB13928
    ApprovedInvestigational

    as the first approved drug for such use since 2014. … Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017.[L8681] The tablet formulation was approved for oral administration in September 2019.

  6. Drug

    Pyridostigmine

    go.drugbank.com/drugs/DB00545
    ApprovedInvestigational

    [A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet.

  7. Drug

    Acetylene

    go.drugbank.com/drugs/DB15906
    ApprovedWithdrawn

    Mixtures: iCOmas 0,3 % / 0,3 % / 0,3 % Gas zur medizinischen Anwendung, druckverdichtet
  8. Drug

    Ferrous fumarate

    go.drugbank.com/drugs/DB14491
    ApprovedInvestigational

    Used in treatment of iron deficiency anemia.

    Mixtures: Taron-prex Prenatal, Luna Vitamin and Mineral Bar for Women
  9. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Odesivimab (REGN 3471), [Maftivimab] (REGN 3479), and [Atoltivimab] (REGN 3470) in equimolar proportions

  10. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    It was approved in Europe in February 2015, and in the United States on March 21, 2017.